Csl Behring
Clinical trials sponsored by Csl Behring, explained in plain language.
-
Blood clotting drug trial for trauma bleeding halted early
Disease control TerminatedThis study tested a medicine called BE1116 (a 4-factor prothrombin complex concentrate) to see if it could help people with severe bleeding from traumatic injuries survive. The trial planned to include about 1,366 participants who had major bleeding and needed a large blood trans…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 26, 2026 07:35 UTC
-
Hizentra shows promise for rare muscle disease, but study ends early
Disease control TerminatedThis study tested a weekly injection of Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. The goal was to see if it improves symptoms better than a placebo. The study was terminated early, but results suggest the treatmen…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 26, 2026 07:35 UTC
-
Hizentra study for Post-COVID POTS ends early
Disease control TerminatedThis study tested a medicine called Hizentra (IgPro20) to see if it could help people with post-COVID POTS, a condition that causes a fast heart rate and dizziness when standing up. The trial was stopped early and included 16 adults who had POTS symptoms starting within 4 months …
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 18, 2026 12:00 UTC